The worst-case scenario: Bridging repair with a biologic mesh in high-risk patients with very large abdominal wall hernias-a prospective multicenter study.


Journal

Surgery
ISSN: 1532-7361
Titre abrégé: Surgery
Pays: United States
ID NLM: 0417347

Informations de publication

Date de publication:
02 2021
Historique:
received: 25 05 2020
revised: 25 08 2020
accepted: 31 08 2020
pubmed: 18 10 2020
medline: 23 4 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

While modern techniques allow midline fascial closure for most abdominal hernias, a bridge repair with mesh may be the only alternative in very large defects. When the risk of infection is high, the use of prosthetic mesh is controversial. We aim to examine outcomes after bridge repair of very large abdominal hernias at high risk for postoperative infection with a second-generation biologic mesh. Prospective, multicenter, single-arm study of patients with very large abdominal hernias who received bridge repair with a neonatal bovine dermis mesh. Primary outcome was hernia recurrence, as identified on computed tomography 1 year after the operation. Secondary outcomes included mesh laxity, surgical site occurrences, and any other mesh-related complications. Independent risk factors of the outcomes were determined by univariate and multivariable analyses. A total of 117 bridge repair patients were enrolled with a mean defect size of 442.5 ± 254.2 cm In patients with very large abdominal hernias and at high risk for postoperative infection, who cannot undergo midline fascial closure, a bridge repair with neonatal bovine dermis mesh offers an acceptable profile in terms of hernia recurrence and wound occurrences.

Sections du résumé

BACKGROUND
While modern techniques allow midline fascial closure for most abdominal hernias, a bridge repair with mesh may be the only alternative in very large defects. When the risk of infection is high, the use of prosthetic mesh is controversial. We aim to examine outcomes after bridge repair of very large abdominal hernias at high risk for postoperative infection with a second-generation biologic mesh.
METHODS
Prospective, multicenter, single-arm study of patients with very large abdominal hernias who received bridge repair with a neonatal bovine dermis mesh. Primary outcome was hernia recurrence, as identified on computed tomography 1 year after the operation. Secondary outcomes included mesh laxity, surgical site occurrences, and any other mesh-related complications. Independent risk factors of the outcomes were determined by univariate and multivariable analyses.
RESULTS
A total of 117 bridge repair patients were enrolled with a mean defect size of 442.5 ± 254.2 cm
CONCLUSION
In patients with very large abdominal hernias and at high risk for postoperative infection, who cannot undergo midline fascial closure, a bridge repair with neonatal bovine dermis mesh offers an acceptable profile in terms of hernia recurrence and wound occurrences.

Identifiants

pubmed: 33066982
pii: S0039-6060(20)30603-6
doi: 10.1016/j.surg.2020.08.036
pii:
doi:

Substances chimiques

Biocompatible Materials 0

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

318-324

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

George C Velmahos (GC)

Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: gvelmahos@mgh.harvard.edu.

Demetrios Demetriades (D)

Los Angeles County and University of Southern California Medical Center, Keck School of Medicine, Los Angeles, CA.

Eric Mahoney (E)

Boston Medical Center, Boston University School of Medicine, MA.

Peter Burke (P)

Boston Medical Center, Boston University School of Medicine, MA.

Kimberly Davis (K)

Yale University Hospital, Yale University School of Medicine, New Haven, CT.

Andreas Larentzakis (A)

Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Karim Fikry (K)

Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Mohamad El Moheb (M)

Massachusetts General Hospital, Harvard Medical School, Boston, MA.

Stephen Kovach (S)

Hospital of the University of Pennsylvania, Philadelphia, PA.

Martin Schreiber (M)

Oregon Health and Science University, Portland, OR.

Moustafa Hassan (M)

State University of New York Upstate Medical Center, Syracuse, NY.

Roxie Albrecht (R)

University of Oklahoma Health Sciences Center, Oklahoma City, OK.

Andrew Dennis (A)

Cook County Hospital, Chicago, IL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH